Amneal Accelerates Growth with Kashiv BioSciences Deal
Bridgewater, New Jersey, USA – April 22, 2026 In a transformative move within the global biopharmaceutical landscape, Amneal Pharmaceuticals...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Bridgewater, New Jersey, USA – April 22, 2026 In a transformative move within the global biopharmaceutical landscape, Amneal Pharmaceuticals...
Brisbane, California, USA, April 6, 2026 First-in-Human Study Targets Inflammation Pathways In a significant milestone for clinical-stage biotech innovation,...
San Diego & Redwood City, California, USA, April 6, 2026 Strategic Acquisition Strengthens Rare Disease Leadership In a major...
INDIANAPOLIS | January 7, 2026 — Eli Lilly and Company has announced an agreement to acquire Ventyx Biosciences, a...
TORONTO | January 5, 2026 — PharmaDrug Inc. has completed the acquisition of an initial 19.9% equity interest in...
NEW YORK, NY — November 14, 2025 — Pfizer announced it has completed its acquisition of Metsera, Inc., strengthening...
